Amgen vs Visa: Founders, CEOs and History
Amgen was founded in 1980 by George B. Rathmann, William K. Bowes Jr. and is led by Robert A. Bradway. Visa was founded in 1958 by Dee Hock and is led by Ryan McInerney.
Company facts
Founders
Amgen
George B. Rathmann
Amgen, originally incorporated as Applied Molecular Genetics, was founded in 1980 not by a single scientist, but by a calculated syndicate of venture capitalists and academics trying to commercialize the brand-new science of recombinant DNA.
William K. Bowes Jr.
William K. Bowes Jr. Was the venture capital strategist whose vision catalyzed Amgen's formation.
Visa
Dee Hock
Dee Hock (1929-2022) was the founding CEO of National BankAmericard Inc., the bank-owned company that took over the BankAmericard licensing system from Bank of America in 1970 and adopted the Visa name in 1976.
CEOs and their tenures
Amgen
- George B. Rathmann1980–1988
Chief Executive Officer
George Rathmann, a physical chemist who had run research and development at Abbott Laboratories, was named Amgen's first chief executive in 1980 and worked from a small trailer so that laboratory space could go to scientists.
Source - Gordon M. Binder1988–2000
Chief Executive Officer
Gordon Binder joined Amgen as chief financial officer in 1982 and led its June 1983 initial public offering.
Source - Kevin W. Sharer2000–2012
Chief Executive Officer
Kevin Sharer joined Amgen in 1992 as president and chief operating officer and became chairman and chief executive in 2000.
Source - Robert A. Bradway2012–present
Chairman and Chief Executive Officer
Robert Bradway became chief executive on May 23, 2012, succeeding Kevin Sharer as the fourth CEO in Amgen's history, and added the chairmanship at the start of 2013.
Source
Visa
- Alfred F. Kelly Jr.2016–2023
Chief Executive Officer
Serving as CEO from 2016 to 2023, he heavily modernized the massive legacy network, aggressively integrating fintechs and preparing the network to process highly complex cryptocurrency transactions.
Source - Ryan McInerney2023–present
Chief Executive Officer
McInerney joined Visa in 2013 as president after senior roles at JPMorgan Chase and became chief executive on February 1, 2023, succeeding Alfred F. Kelly Jr.
Source
Timeline: Amgen and Visa side by side
1958Visa
BankAmericard launched
Bank of America launched BankAmericard, the direct predecessor to Visa.
1976Visa
Visa name adopted
The network adopted the Visa name to support international acceptance and brand consistency.
1980Amgen
Applied Molecular Genetics is incorporated
Applied Molecular Genetics (AMGen) was incorporated on April 8, 1980 in Thousand Oaks, California, as the idea of venture capitalist William K. Bowes Jr. and a group of scientific collaborators.
1983Amgen
Nasdaq listing and the erythropoietin clone
Amgen completed its initial public offering on June 17, 1983, raising nearly US$40 million under chief financial officer Gordon Binder, and formally shortened its name to Amgen.
1984Amgen
Kirin-Amgen joint venture formed
Amgen and Kirin Brewery Company of Japan formed Kirin-Amgen in 1984 as a joint venture for the worldwide commercialization of erythropoietin.
1985Amgen
G-CSF cloned, leading to Neupogen
While Fu-Kuen Lin's team worked on erythropoietin, researcher Larry Souza and his group cloned and expressed human granulocyte colony-stimulating factor in 1985.
1989Amgen
FDA approves Epogen
The FDA approved Epogen (epoetin alfa) on June 1, 1989 for anemia in patients with chronic kidney failure on dialysis. It was the first commercial recombinant human erythropoietin. Epogen's U.S.
1991Amgen
Neupogen approved, giving Amgen a second franchise
The FDA approved Neupogen (filgrastim) in February 1991. By stimulating white blood cell production it reduced the risk of infection in cancer patients with chemotherapy-induced neutropenia.
1991Amgen
Amgen wins the erythropoietin patent fight
On March 6, 1991 the U.S. Court of Appeals for the Federal Circuit upheld the Kirin-Amgen erythropoietin patent and ruled against Genetics Institute in Amgen v. Chugai Pharmaceutical and Genetics Institute.
2001Amgen
FDA approves Aranesp, the longer-acting EPO
Aranesp (darbepoetin alfa), an erythropoietin analogue with modified glycosylation and a longer half-life, was approved in 2001. Less frequent dosing than Epogen improved convenience and gave Amgen a newer, higher-priced product to migrate patients toward.
2002Amgen
US$16 billion Immunex acquisition brings Enbrel in-house
Amgen completed its acquisition of Immunex Corporation on July 16, 2002, the largest biotechnology deal to that point at about US$16 billion in stock and cash.
2008Visa
Visa IPO
Visa became a public company, changing the economics from a bank association structure to a shareholder-owned company.
2010Amgen
Prolia and XGEVA create the bone health franchise
The FDA approved Prolia (denosumab) for postmenopausal osteoporosis in June 2010 and XGEVA, the same molecule at a higher dose, for prevention of skeletal-related events in cancer patients in November 2010.
2016Visa
Alfred F. Kelly Jr. becomes CEO
Alfred F. Kelly Jr. became CEO of Visa in 2016. Chief executive of Visa from December 2016 to January 2023, when Ryan McInerney succeeded him; Kelly then served as executive chairman.
2019Amgen
US$13.4 billion purchase of Otezla from Celgene
Amgen agreed in August 2019 to buy worldwide rights to Otezla (apremilast) from Celgene for US$13.4 billion in cash, or about US$11.2 billion net of the present value of US$2.2 billion of anticipated future cash tax benefits, and closed on November 21, 2019.
2020Amgen
Amgen joins the Dow Jones Industrial Average
Amgen replaced Pfizer in the Dow Jones Industrial Average on August 31, 2020, becoming one of the thirty components in the index. Inclusion recognized the scale Amgen had reached and added passive demand from Dow-tracking funds.
2020Visa
Acquired Plaid (abandoned)
Visa acquired Plaid (abandoned) for $5.3 billion. Visa agreed in January 2020 to buy US data-connectivity fintech Plaid for USD 5.3 billion.
2022Visa
Tink acquisition
Visa completed its purchase of Stockholm-based open banking platform Tink in March 2022.
2023Amgen
US$27.8 billion Horizon Therapeutics acquisition closes
Amgen completed the acquisition of Horizon Therapeutics plc on October 6, 2023 for US$116.50 per share in cash, an equity value of about US$27.8 billion, after settling FTC litigation with a behavioral consent decree.
2023Visa
Ryan McInerney becomes CEO
Ryan McInerney became Visa's CEO after serving as president.
2024Amgen
Imdelltra becomes the first T-cell engager for small cell lung cancer
The FDA granted accelerated approval to tarlatamab, sold as Imdelltra, on May 16, 2024 for extensive stage small cell lung cancer that has progressed on or after platinum-based chemotherapy.
2025Amgen
VESALIUS-CV extends the Repatha case to primary prevention
In November 2025 Amgen reported Phase 3 VESALIUS-CV results in more than 12,000 patients with atherosclerosis or diabetes but no prior heart attack or stroke.
2025Visa
Revenue reaches $40.0B
Visa reported $40.0 billion in fiscal 2025 net revenue.
2026Amgen
Medicare price setting reaches Enbrel and Otezla
Enbrel's negotiated Medicare price under the Inflation Reduction Act took effect on January 1, 2026, after it was named in the first round of ten drugs selected for negotiation.
Acquisitions
Amgen
- Horizon Therapeutics plc2023$27.8B
- ChemoCentryx, Inc.2022$3.7B
- Five Prime Therapeutics2021$1.9B
- Celgene Otezla Business2019$13.4B
- Onyx Pharmaceuticals, Inc.2013$10.4B
- DeCODE Genetics2012$415M
Questions about Amgen vs Visa
Who is the CEO of Amgen Inc. and Visa Inc.?
Amgen Inc. is led by Robert A. Bradway and Visa Inc. is led by Ryan McInerney. Both serve as the top executive responsible for the company's strategy, operations, and financial performance.
When was Amgen Inc. founded vs Visa Inc.?
Visa Inc. was founded in 1958 — 22 years before Amgen Inc., which was founded in 1980. Visa Inc.'s longer operating history gives it a deeper track record but also potentially more institutional inertia compared to the younger Amgen Inc..
How many employees does Amgen Inc. have compared to Visa Inc.?
Amgen Inc. employs approximately 31,500 people, while Visa Inc. employs approximately 34,100. Visa Inc. has the larger workforce at 34,100 employees, compared to Amgen Inc.'s 31,500. A higher headcount does not necessarily imply greater efficiency — it often reflects differences in business model (e.g., manufacturing vs. software).
Where are Amgen Inc. and Visa Inc. headquartered?
Both Amgen Inc. and Visa Inc. are headquartered in United States, meaning they operate under the same primary regulatory and tax environment.
Who founded Amgen Inc. and Visa Inc.?
Amgen Inc. was founded by George B. Rathmann, William K. Bowes Jr.. Visa Inc. was founded by Dee Hock.
Which company has a longer operating history — Amgen Inc. or Visa Inc.?
Visa Inc. has been operating for approximately 68 years, making it the more established of the two companies. Amgen Inc. has been in operation for around 46 years. A longer operating history often signals greater institutional resilience and brand recognition, though it can also mean slower adaptation to new market conditions.
Figures come from each company's filings and the sources linked beside them. Amounts reported in another currency are shown in US dollars at an approximate rate and marked with ~. Back to the Amgen vs Visa overview